Generation Bio Co. (GBIO) Financial Statements (2025 and earlier)

Company Profile

Business Address 301 BINNEY STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments185,223264,364279,091375,145262,327
Cash and cash equivalent76,30166,44693,171375,14562,889
Short-term investments108,922197,918185,920 199,438
Receivables3,4853,960395  
Prepaid expense 9876801,180  
Asset, held-for-sale, not part of disposal group 163    
Other current assets 160290259  
Other undisclosed current assets2,8853,3246,0914,0415,408
Total current assets:192,903272,618287,016379,186267,735
Noncurrent Assets
Operating lease, right-of-use asset20,31069,85259,20865,143 
Property, plant and equipment15,29325,79922,21525,88623,781
Restricted cash and investments2,1525,7915,6925,6922,051
Deferred costs  433434461336
Other noncurrent assets5392651,699403252
Total noncurrent assets:38,294102,14089,24897,58526,420
TOTAL ASSETS:231,197374,758376,264476,771294,155
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,98016,4629,67910,5647,357
Employee-related liabilities7,9707,5796,150
Accounts payable1,4082,3466622,023267
Accrued liabilities6,57214,1161,047962940
Deferred revenue10,58212,919   
Deferred rent credit     1,389
Other liabilities2,658406426676702
Other undisclosed current liabilities13,83510,1279,0457,5681,772
Total current liabilities:35,05539,91419,15018,80811,220
Noncurrent Liabilities
Long-term debt and lease obligation:    76,217 
Liabilities, other than long-term debt109,938131,71674,621 14,922
Deferred revenue29,16141,942   
Deferred rent credit     14,922
Other liabilities 223    
Operating lease, liability80,55489,77474,62176,217 
Other undisclosed noncurrent liabilities    (76,217) 
Total noncurrent liabilities:109,938131,71674,62176,21714,922
Total liabilities:144,993171,63093,77195,02526,142
Equity
Equity, attributable to parent86,204203,128282,493381,746268,013
Common stock77665
Additional paid in capital789,083774,224727,335689,866456,974
Accumulated other comprehensive income (loss)159274(83) 9
Accumulated deficit(703,045)(571,377)(444,765)(308,126)(188,975)
Total equity:86,204203,128282,493381,746268,013
TOTAL LIABILITIES AND EQUITY:231,197374,758376,264476,771294,155

Income Statement (P&L) ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues19,8925,904   
Gross profit:19,8925,904   
Operating expenses(162,282)(144,467)(141,182)(119,101)(81,114)
Operating loss:(142,390)(138,563)(141,182)(119,101)(81,114)
Nonoperating income (expense)10,72211,9514,543(50)591
Investment income, nonoperating7,8539,3402,289(766)(249)
Loss from continuing operations before income taxes:(131,668)(126,612)(136,639)(119,151)(80,523)
Income tax expense (38,774)(37,684)(38,956)(37,934)(27,855)
Other undisclosed loss from continuing operations     
Loss from continuing operations:(170,442)(164,296)(175,595)(157,085)(108,378)
Loss before gain (loss) on sale of properties:(157,085)(108,378)
Other undisclosed net income38,77437,68438,95637,93427,855
Net loss available to common stockholders, diluted:(131,668)(126,612)(136,639)(119,151)(80,523)

Comprehensive Income ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(131,668)(126,612)(136,639)(119,151)(80,523)
Comprehensive loss:(131,668)(126,612)(136,639)(119,151)(80,523)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(115)357(83)(9)9
Comprehensive loss, net of tax, attributable to parent:(131,783)(126,255)(136,722)(119,160)(80,514)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: